


Healthcare Industry News: IIb/IIIa
News Release - October 9, 2013
First Patient Enrolled in Phase III Trial Evaluating The Medicines Company's Angiomax(R) (Bivalirudin) in Patients Undergoing Peripheral Endovascular Procedures
Source: The Medicines Company
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
